Skip to content

NYSE · large · thesis board

NVO Novo Nordisk

Incretin combination + factor mimetics

View race

Thesis

Editorial summary — not a primary filing

Obesity and hemophilia franchises; next combos defend GLP-1 leadership.

Next gate

2026-10-10Company-guidedPh3 readout

Phase 3 combo data

58 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~22 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~730d)100%
Days to gate (58d)8%
Show math

$12.0B cash ÷ $500M/mo burn ≈ 730 days. Source: curated SEC quarter figures.

Cash $12.0B as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved
Secondary assets (1)
  • Mim8 factor mimetic · Filed · hemophilia

Rivals in this race

Open race →
LLYPh3okAMGNPh3okVKTXPh2ok

Risks

  • Lilly competition
  • Compounding / compounding policy
  • Supply
  • Pipeline timing

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT05567726as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01